Telix Pharmaceuticals (ASX: TLX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Telix Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Telix Pharmaceuticals (ASX: TLX)
Latest News
Share Gainers
Why Capitol Health, Capricorn Metals, Credit Clear, and Telix shares are storming higher
Broker Notes
Why these 3 ASX 200 shares just earned substantial broker upgrades
Healthcare Shares
Telix Pharmaceuticals share price sinks on unexpected Nasdaq news
Healthcare Shares
Why this broker just upgraded Telix shares to a buy rating
Healthcare Shares
Why is the Telix Pharmaceuticals share price frozen today?
Opinions
4 top ASX 200 stocks to buy now for the AI revolution
Healthcare Shares
3 ASX 300 healthcare stocks 'well positioned to outperform'
Healthcare Shares
2 ASX biotech shares that could be the next Telix Pharmaceuticals
Healthcare Shares
Telix Pharmaceuticals share price jumps to record high on Nasdaq IPO launch
Share Gainers
3 high-flying ASX shares that could keep on climbing
Share Market News
How ASX shares vs. property performed in May
Share Gainers
Sell in May and go away? Not for these top 3 ASX 200 stocks!
Frequently Asked Questions
-
No, Telix does not pay dividends at this time.
-
Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.
TLX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Telix Pharmaceuticals
Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe.
The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States.
